NOL10

Across TCGA pan-cancer cohorts, NOL10 mass-spec protein is linked to patient survival in 7 of 34 cancer types, making it a survival-associated NOL10 data layer compared with 25 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher NOL10 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated NOL10 expression acts as an unfavorable survival marker, although some lineages such as LSCC and COAD show a favorable association.

CCRCC, LSCC, and HNSC are the cancer types where NOL10 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Median	III,IV	0.701	1.000	<.001	99	view →
LSCC	DFS	Median	II,III,IV	0.851	0.526	.004	23	view →
HNSC	DFS	Quartile	IV	0.535	0.862	.016	16	view →
LUAD	OS	Median	II,III,IV	0.337	0.908	.002	13	view →
COAD	DFS	Median	III,IV	1.000	0.846	.049	6	view →
PDAC	OS	Quartile	II,III,IV	0.399	0.654	.009	5	view →
GBM	OS	Tertile	All	0.789	0.872	.048	1	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

NOL10–CCRCC (DFS)

Open the CCRCC breakdown →